<ruby id="jhf9f"></ruby>

      <pre id="jhf9f"><ruby id="jhf9f"></ruby></pre>

        Pipeline

        Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

        Pipeline

        HIV / AIDS

        Gilead is committed to pursuing innovation in HIV across the spectrum of care. We are working to address remaining needs in both prevention and treatment. And, we are focused on discovery research that could potentially, one day, lead to a cure.

        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

        • Emtricitabine and tenofovir alafenamide

          Potential Indication: PrEP

          Phase 1
          Phase 2
          Phase 3
        • GS-6207 (Capsid Inhibitor)

          Potential Indication: HIV/AIDS

          Phase 1
          Phase 2
          Phase 3
        • Vesatolimod (TLR-7 agonist)

          Potential Indication: HIV/AIDS

          Phase 1
          Phase 2
          Phase 3
        • Elipovimab (bNab)

          Potential Indication: HIV/AIDS

          Phase 1
          Phase 2
          Phase 3

        Liver Diseases

        Gilead’s liver disease research focuses on investigating medicines for patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) and for potentially curing patients chronically infected with the hepatitis B virus (HBV).

        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

        • Cilofexor (FXR agonist)

          Potential Indication: NASH

          Phase 1
          Phase 2
          Phase 3
        • Cilofexor (FXR agonist)

          Potential Indication: Primary Biliary Cirrhosis

          Phase 1
          Phase 2
          Phase 3
        • Cilofexor (FXR agonist)

          Potential Indication: Primary Sclerosing Cholangitis

          Phase 1
          Phase 2
          Phase 3
        • Firsocostat (ACC Inhibitor)

          Potential Indication: NASH

          Phase 1
          Phase 2
          Phase 3
        • Selgantolimod (TLR-8 agonist)

          Potential Indication: HBV

          Phase 1
          Phase 2
          Phase 3
        • GS-4224 (PD-L1 Inhibitor)

          Potential Indication: HBV

          Phase 1
          Phase 2
          Phase 3

        Hematology / Oncology

        Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. Following the 2017 acquisition of Kite Pharma, Inc., our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors.

        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

        • Axicabtagene ciloleucel

          Trial: ZUMA-5 Potential Indication: Indolent NHL

          Phase 1
          Phase 2
          Phase 3
        • Axicabtagene ciloleucel

          Trial: ZUMA-6 Potential Indication: DLBCL (+PD-L1 mAb)

          Phase 1
          Phase 2
          Phase 3
        • Axicabtagene ciloleucel

          Trial: ZUMA-7 Potential Indication: 2nd line DLBCL

          Phase 1
          Phase 2
          Phase 3
        • Axicabtagene ciloleucel

          Trial: ZUMA-11, Potential Indication: DLBCL (+4-1BB)

          Phase 1
          Phase 2
          Phase 3
        • Axicabtagene ciloeucel

          Trial: ZUMA-12 Potential Indication: 1st line DLBCL

          Phase 1
          Phase 2
          Phase 3
        • Axicabtagene ciloleucel

          Trial: ZUMA-14 Potential Indication: DLBCL (+rituximab or lenalidomide)

          Phase 1
          Phase 2
          Phase 3
        • KTE-X19

          Trial: ZUMA-2 Potential Indication: MCL

          Phase 1
          Phase 2
          Phase 3
        • KTE-X19

          Trial: ZUMA-3 Potential Indication: Adult ALL

          Phase 1
          Phase 2
          Phase 3
        • KTE-X19

          Trial: ZUMA-4 Potential Indication: Pediatric ALL

          Phase 1
          Phase 2
          Phase 3
        • KTE-X19

          Trial: ZUMA-8 Potential Indication: CLL

          Phase 1
          Phase 2
          Phase 3
        • KITE-718 (MAGE A3/A6)

          Potential Indication: Solid Tumor

          Phase 1
          Phase 2
          Phase 3
        • KITE-439 (HPV E7)

          Potential Indication: Solid Tumor

          Phase 1
          Phase 2
          Phase 3
        • GS-1423 (bi-specific antibody)

          Potential Indication: Solid Tumor

          Phase 1
          Phase 2
          Phase 3
        • GS-4224 (oral PD-L1 inhibitor)

          Potential Indication: Solid Tumor

          Phase 1
          Phase 2
          Phase 3

        Inflammation / Respiratory

        Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders.

        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

        • Filgotinib (JAK1 inhibitor)

          Potential Indication: Rheumatoid Arthritis

          Phase 1
          Phase 2
          Phase 3
        • Filgotinib (JAK1 inhibitor)

          Potential Indication: Crohn's Disease

          Phase 1
          Phase 2
          Phase 3
        • Filgotinib (JAK1 inhibitor)

          Potential Indication: Ulcerative Colitis

          Phase 1
          Phase 2
          Phase 3
        • Filgotinib (JAK-1 inhibitor)

          Potential Indication: Psoriatic Arthritis

          Phase 1
          Phase 2
          Phase 3
        • Filgotinib (JAK1 inhibitor)

          Potential Indication: Inflammatory Diseases

          Phase 1
          Phase 2
          Phase 3
        • Filgotinib (JAK-1 inhibitor)

          Potential Indication: Ankylosing Spondylitis

          Phase 1
          Phase 2
          Phase 3
        • GS-9876 (Syk inhibitor)

          Potential Indication: Sjogren’s Syndrome

          Phase 1
          Phase 2
          Phase 3
        • GS-9876 (Syk inhibitor)

          Potential Indication: Lupus

          Phase 1
          Phase 2
          Phase 3
        • GS-4875 (TPL2 inhibitor)

          Potential Indication: Ulcerative Colitis

          Phase 1
          Phase 2
          Phase 3
        • GLPG-1690

          Potential Indication: Idiopathic Pulmonary Fibrosis

          Phase 1
          Phase 2
          Phase 3
        • GLPG-1690

          Potential Indication: Systemic Sclerosis

          Phase 1
          Phase 2
          Phase 3
        • Selonsertib (ASK-1 inhibitor)

          Potential Indication: DKD

          Phase 1
          Phase 2
          Phase 3

        Other

        Gilead is collaborating with U.S. Department of Defense, Centers for Disease Control and Prevention, and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases, including Ebola.

        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

        • Remdesivir (GS-5734, Nuc inhibitor)

          Potential Indication: Ebola Virus Infection

          Phase 1
          Phase 2
          Phase 3

        Some of the content on this page is not intended for users outside the US.

        天天狠天天透天天伊人